Navigation Links
Arrowhead Subsidiaries Insert & Calando Present Data on,Cyclosert Drug Delivery System at AACR Meeting

Novel Systems May Provide Cancer Patients With Improved Potential to Battle Their Disease

PASADENA, Calif., April 16, 2007 /PRNewswire-FirstCall/ -- Arrowhead Research Corporation announced today that two of its majority-owned subsidiaries, Insert Therapeutics Inc. and Calando Pharmaceuticals Inc., are presenting data at the 2007 American Association for Cancer Research (AACR) Annual Meeting. The presentations summarize the latest research findings on two anticancer therapies currently under development. Both therapies employ a novel delivery system called Cyclosert(TM), developed at the and exclusively licensed to Insert Therapeutics and, through Insert, to Calando.

"We are pleased that our companies have outstanding data to present at this prestigious conference," said R. Bruce Stewart, Chairman and Chief Executive Officer of Arrowhead. "We see great promise going forward for the treatment of cancer using our delivery system."

Cyclosert is the first nanoparticle drug transport platform to be designed de novo and synthesized specifically to overcome limitations in existing technologies used for the systemic transport of therapeutics to targeted sites within the body. Based on small cyclic repeating molecules of glucose called cyclodextrins, Cyclosert promotes the ability of cytotoxic drugs to inhibit the growth of human cancer cells while reducing toxicity and remaining non-immunogenic at therapeutic doses. In particular, the system is designed to reduce the toxicity of the drugs until they actually reach the targeted tumor cells where the active drug is released in a controlled fashion.

Insert's Chief Scientific Officer, Thomas Schluep, Sc.D., will present data from in vitro and animal studies using the Cyclosert system to deliver tubulysin A, a potent, but highly toxic, antitumor agent. In vitro studies have shown the tubulysin-Cyclosert conjugate to be effective against multiple human c
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from Human Clinical Trials for New Cancer Drug
2. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
3. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
4. Dharma Therapeutics Shows IDDS Is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in Their Phase 2 Clinical Trial
5. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
6. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
7. Vastox Awarded £400,000 Grant to Support R&D at Carbohydrate Chemistry Facility
8. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
9. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
10. Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years
11. Calando Pharmaceuticals Announces Preclinical Efficacy and Safety Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting
Post Your Comments:
(Date:5/28/2015)... 28, 2015  Eli Lilly and Company (NYSE: LLY ... tender offer for up to $1.6 billion aggregate principal amount ... approximately $1.45 billion in aggregate principal amount of the notes ... validly withdrawn on or prior to 5:00 p.m., ... the early tender date for the offer. ...
(Date:5/27/2015)... Research and Markets ( ... the  "2015 Strategies in the UK Nucleic ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,  ... NAT laboratory practice, as well as key ... with significant market impact during the next ...
(Date:5/27/2015)... , May 27, 2015 ... has announced the addition of the  "North ... Forecasts (2014 - 2019)"  report to ... ,  , ,Mammography is a detailed type ... system to inspect breasts. A mammography exam, ...
Breaking Medicine Technology:Lilly Announces the Early Results of Its Cash Tender Offer 2Lilly Announces the Early Results of Its Cash Tender Offer 3Lilly Announces the Early Results of Its Cash Tender Offer 4Lilly Announces the Early Results of Its Cash Tender Offer 5North America Mammography Market - Growth, Trends And Forecasts (2014 - 2019) 2
... Oct. 13 The Care Continuum Alliance ... Award for the "Greatest Impact on Health" at ...  The ALL/PHASE protocol, which utilizes low-cost and generic medications ... successfully implemented in Kaiser Permanente communities, including those served ...
... Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna -- OOSTERHOUT, Netherlands, Oct. 13 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Medicine Technology:Kaiser Permanente's ALL/PHASE Initiative Wins 2010 Care Continuum Alliance Quality Impact Award for Greatest Impact on Health 2Kaiser Permanente's ALL/PHASE Initiative Wins 2010 Care Continuum Alliance Quality Impact Award for Greatest Impact on Health 3Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 2Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 3Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 4Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 5Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 6Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 7Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 8Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 9
(Date:5/28/2015)... 28, 2015 Hexagon Geospatial is pleased ... a provider of engineering, spatial data and mapping services, ... thousands of point clouds for urban change assessments in ... 2014, the BHI Spatial Data Division implemented a countywide ... aerial imagery. Collected by a variety of different digital ...
(Date:5/28/2015)... 2015 Cancer survivors who participated in ... physical activity, fitness and quality of life, according to ... Center and Jennifer Ligibel, MD, senior physician in the ... Cancer Institute. The findings will be presented at this ... Annual Meeting in Chicago. , The study, ...
(Date:5/28/2015)... May 28, 2015 The MIT Sloan ... study featuring Healthcare IQ. Members of the MIT CISR ... management team to develop the case study about Healthcare ... analytics. , The case study, ‘Healthcare IQ: Competing as ... from its beginning as a hospital financial software provider ...
(Date:5/28/2015)... Dallas urologist Mark Allen, MD ... patient education website NORTHTEXASUROLOGIST.COM developed by ... readily access current educational information on various urological ... incontinence, prostate cancer treatment, robotic surgery and female ... to educate patients on urological conditions and treatments, ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Atlanta-based Thrive ... be breaking ground this summer on an innovative new ... on resident engagement and connectivity in a unique, resort-like ... of innovative technology and southern hospitality to create a ... The 93 unit community will feature luxuriously appointed resident ...
Breaking Medicine News(10 mins):Health News:Hexagon Geospatial Supports Urban Change Detection Programs in New Mexico 2Health News:Hexagon Geospatial Supports Urban Change Detection Programs in New Mexico 3Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 2Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 3Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 4Health News:Healthcare IQ, the “Switzerland” of Healthcare Spend Analytics, Featured in MIT Case Study 2Health News:Healthcare IQ, the “Switzerland” of Healthcare Spend Analytics, Featured in MIT Case Study 3Health News:Mark Allen MD, Dallas Urologist, Launches Updated Patient Education Website With a Focus on Prostate Cancer and Erectile Dysfunction Treatment 2Health News:Thrive Announces Innovative New Senior Living Community in Huntsville, AL 2
... most resistant leukemia can be treated with a superior ... fails, as showed by the clinicians at the St. ... Jude technique allows blood stem cells to come from ... aggressive, toxic treatments that usually must accompany the transplant. ...
... health benefits versus risks of an oral medicine widely prescribed ... // ,The drug — called pioglitazone — is marketed ... and Eli Lilly and Co. under the trade name Actos. ... at least 24 weeks of pioglitazone treatment in people with ...
... Chicago chemists have demonstrated for the first time how ... a few chemical reactions to predict when and where ... technique that allows them to probe blood clotting on ... a unit of measurement much narrower than the diameter ...
... in the gut has been found to be an ... to researchers at Cedars-Sinai Medical Center. ,The ... of the Annals of Internal Medicine It is ... after end of the course of treatment has ended. ...
... he would prefer not step in to fast-track a merger ... a meeting with Tony Abbott and Goulburn Murray politicians yesterday. ... and Victorian governments has still not revealed a common plan ... the border work as one. ,Mr Abbott states that ...
... cancer patient, Lisa Norris, 16 has succumbed to the accidental ... was discovered//. ,Lisa Norris, from Girvan in Ayrshire, ... She was admitted to the Beatson Oncology Centre in Glasgow, ... radiation treatments in the past 20 years. ,Following a ...
Cached Medicine News:Health News:Partial-match cell transplants for kids with resistant leukemia 2Health News:Partial-match cell transplants for kids with resistant leukemia 3Health News:Widely Prescribed Diabetes Drug Falls Short of Promise, Says New Review 2Health News:Widely Prescribed Diabetes Drug Falls Short of Promise, Says New Review 3Health News:Predicting the Dynamics of Clotting in Human Blood 2Health News:Predicting the Dynamics of Clotting in Human Blood 3Health News:IBS Sufferers Benefited by Non-Absorbable Antibiotics 2Health News:Cancer patient Dies of Massive Radiation Overdose 2
... has been designed so the surgeon can ... tissue away from the operative surface. It ... without stay-sutures or assistance. This controlled versatility ... to do other tasks, which will broaden ...
... The PowerPro® Battery System is a ... line of powered surgical instruments. The PowerPro ... software controlled battery powered instrument available on ... power system specifically designed to meet the ...
... GE OEC, the market leader ... decades of imaging experience and advanced ... with its latest entry, the MiniView ... extremity imaging has the workstation components ...
Lightweight & portable, compact station. Accurate and speedy measurement, auto-shot function, AI measuring function, focusing indicator....
Medicine Products: